January 1, 2015Circulation Journal279 citationsOpen Access

Ticagrelor vs. Clopidogrel in Japanese, Korean and Taiwanese Patients With Acute Coronary Syndrome　– Randomized, Double-Blind, Phase III PHILO Study –

SGShinya Goto CHChien‐Hua Huang SPSeung‐Jung Park

Structured PICO

Does ticagrelor improve safety and efficacy compared to clopidogrel in East Asian patients with acute coronary syndrome?

Population

Patients with Acute Coronary Syndrome (ACS) from Japan, Taiwan, and South Korea

Intervention

Ticagrelor

Comparator

Clopidogrel

Outcome

Primary safety and efficacy endpoints (not explicitly defined in abstract)

In an East Asian ACS population, ticagrelor did not significantly improve safety or efficacy compared to clopidogrel, though results were limited by small sample size and low event rates.

Abstract

In ACS patients from Japan, Taiwan and South Korea, event rates of primary safety and efficacy endpoints were higher, albeit not significantly, in ticagrelor-treated patients compared with clopidogrel-treated patients. This observation could be explained by the small sample size, imbalance in clinical characteristics and low number of events in the PHILO population.

Ask AI

Helpful

Bookmark

View Full Paper